|
|||||
|
|
Preventing central nervous system metastases in non-small cell lung cancer |
|
| Authors: | Pawe? Krawczyk Renata Duchnowska Marcin Nico? Dariusz Kowalski Kamila Wojas-Krawczyk |
| Institution: | 1. Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, Lublin, Poland;2. Department of Oncology, Military Institute in Warsaw, Warszawa, Poland;3. Department of Lung and Chest Tumors, Oncology Centre – Institute in Warsaw, Warszawa, Poland |
| Abstract: | Introduction: There are no effective central nervous system (CNS) metastases prevention methods in lung cancer patients. Prophylactic cranial irradiation has a limited effectiveness and relatively high toxicity. Systemic chemotherapy is not relevant in reducing the risk of CNS in lung cancer patients. The understanding of molecular background of brain metastases in non-small cell lung cancer (NSCLC) patients could contribute to the development of personalized treatments for such patients. Areas covered: This article summarizes the latest clinical trials concerning the use of radiotherapy, chemotherapy, molecularly targeted therapies, and immunotherapy in lung cancer patients, with particular consideration of brain lung cancer metastasis prevention. The literature search was undertaken via PubMed and EMBASE searches and relevant articles are included in this review. Expert commentary: The recent data supports that EGFR-TKIs and ALK inhibitors are clinically relevant for first-line treatment to prevent and treat CNS metastases in molecularly selected NSCLC patients. In the future, high hopes for the prevention of CNS metastases in NSCLC patients are associated with immunotherapy concerning immune check-points inhibitors. |
| Keywords: | Central nervous system metastases non-small cell lung cancer radiotherapy chemotherapy molecularly targeted therapy immunotherapy |